Merck’s Animal Health Arm Gains FDA Nod for EXZOLT™ CATTLE‑CA1 Topical Parasiticide

Merck & Co.’s (NYSE: MRK) animal health division recently secured conditional approval from the U.S. Food and Drug Administration (FDA) for EXZOLT™ CATTLE‑CA1 (fluralaner topical solution), a new isoxazoline‑class parasiticide for cattle. The approval, announced on October 12, 2026, positions the product as a notable addition to Merck’s animal health portfolio focused on livestock health management. The conditional approval status indicates the FDA has granted temporary authorization pending further data or confirmatory studies, which is standard for emerging veterinary pharmaceuticals.

This development arrives amid Merck’s broader momentum in 2026, characterized by heightened activity within its animal health segment. Earlier in the year, Merck completed the acquisition of TARGAN, a company specializing in poultry biotech devices, for approximately $650 million. The deal, accounted for as an asset acquisition, expands Merck’s capabilities in poultry breeding operations through technologies like WingScan for gender identification and precision ocular spray delivery systems. The acquisition drove a $5.7 billion charge to R&D in Q2 and the first half of 2026, reflecting acquired in‑process research and development without alternative future use. These developments reflect a growing strategic emphasis on innovation within the animal health business. 

While the FDA conditional approval of EXZOLT™ CATTLE‑CA1 does not immediately alter Merck’s pharmaceutical financials, it underscores the ongoing diversification of the company’s growth vectors beyond core human health drugs toward veterinary biotech—and reinforces investor visibility into its animal health pipeline expansion.

Merck’s stock (MRK) traded at $149.88 as of October 21, 2026, reflecting a 1.88 % change. This price provides a recent reference point for investors tracking the stock amid developments in both human and animal health domains.

Looking ahead, stakeholders should watch for commercial rollout details and any confirmatory trial results that the FDA may require to transition EXZOLT™ from conditional to full approval status. Such milestones could further validate the potential of Merck’s animal health innovations to contribute to the company’s long‑term revenue mix.